Following the launch of its latest clinical study in the US, Hemerion has obtained authorization from the ANSM (French National Agency for Medicines and Health Products Safety) to open a new trial center at Lille University Hospital in July 2025.
This opening confirms Hemerion’s ability to work effectively with health authorities on both sides of the Atlantic: a rare asset for a French healthtech company.
Opened in July, the investigation site opened by Hemerion at Lille University Hospital significantly strengthens the capacity to enroll new patients for the HTX-GBM-01 clinical study initiated by Hemerion in the US in collaboration with the University of Pennsylvania Medical Center (UPMC) in Pittsburgh.
The Lille University Hospital, the largest university hospital campus in Europe, is a major player in clinical trials in France, with more than 8,000 patients per year.
The principal investigator is Dr. Enora Vauléon from the Department of Neuro-Oncology at Lille University Hospital. The site is equipped with the latest versions of the Heliance® platform, which benefit from the significant improvements made by Hemerion Therapeutics to its technology over the past five years.
The objective is twofold: to confirm the very encouraging clinical results observed in the initial research conducted by Inserm, Lille University Hospital, and the University of Lille between 2017 and 2020, and, if possible, to improve upon them thanks to advances in Pentalafen® / Heliance® technology.
Clinical development conducted on two continents
The opening of this site illustrates Hemerion’s ability to work effectively with European and US health regulations: a rare asset in the healthtech sector, essential for conducting future market access operations in these two major territories.